Hypogonadism in Men

Practical Primary Care Strategies for Diagnosing and Managing Hypogonadism in Men – Best Practices to Improve Patient Outcomes

Print This Post Print This Post

CME Information


Program Overview

Hypogonadism is characterized by a deficiency or decreased level of endogenous testosterone. This past decade has witnessed a rapidly growing awareness of the important role of testosterone. Testosterone deficiency is associated with a well-documented increase in risk of mortality and detrimental effects on quality of life: loss of energy and libido, erectile dysfunction (ED), joint pain and stiffness, memory impairment, irritability, and depression. In spite of this, hypogonadism remains an underdiagnosed syndrome that, with its links to age, obesity, type 2 diabetes mellitus (T2DM), and metabolic syndromes, is becoming increasingly relevant. Furthermore, less than 10% of affected individuals with hypogonadism have been shown to receive testosterone supplement therapy. It will be increasingly important for clinicians to understand potential differences among available supplement therapies, such as efficacy, convenience, uniformity of dose, and the flexibility of dose modifications that influence adherence.

 

Learning Objectives

After completing this activity, the participant should be better able to:

  1. Identify potential hypogonadism in men based on clinical presentation
  2. Utilize appropriate screening measures and criteria to diagnose hypogonadism in men
  3. Assess available testosterone supplement modalities with respect to their convenience, pharmacokinetic profile, patient preference, safety, and efficacy
  4. Prescribe guideline-recommended testosterone replacement therapy based on convenience, pharmacokinetic profile, patient preference, safety, and efficacy considerations

 


This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.

If you are using a mobile device, this activity may not view properly.

Published August 5, 2014